Targeting Dermatologic Side Effects of Immunotherapy Using Novel Skin Care Products

Read full text
Authors: Marithé Claes, Joy Lodewijckx, Jolien Robijns, Laura Tuts, Melissa Lenaerts, Eline Vandaele, Tim Wessels, Annelies Requilé, Daisy Luyten, Yolanda Verheezen, Eric J. Joosens, Jeroen Mebis
Cited by: 0

Abstract

Objective: Immunotherapy can be accompanied by cutaneous adverse events that negatively impact the patient's quality of life (QoL).This trial aimed to evaluate the efficacy of two novel skin care products in preventing and managing cutaneous adverse events associated with immunotherapy.Methods: An interventional, open-label, single-group, pretest-posttest study was conducted at the Jessa Hospital (Belgium) involving cancer patients receiving immunotherapy (n=75).Patients applied the skin care products daily for three weeks.A researcher evaluated skin toxicity using the National Cancer Institute -Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0.Questionnaires assessed the frequency and severity of their symptoms (Numeric Rating Scale, NRS), the patient's QoL (Dermatology Life Quality Index, DLQI, and Skindex-29), the Patient Benefit Index, and patient satisfaction (NRS).Results: The CTCAE and NRS showed that pruritus and xerosis were the most frequently observed skin toxicities.According to the NCI-CTCAE, an improvement was detected in the grade of pruritus and xerosis after applying the novel emollients (P

Fields of Study & Subjects

Dermatology and Skin Diseases Psoriasis: Treatment and Pathogenesis Skin Protection and Aging

Publication details

Journal / source
Journal of Cancer
Volume
17
Issue
2
Pages
197–205
Publication date
1 January 2026
Language
EN